Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CRWE, CBMX, NBY, ATHX Stock Market Update Compliments of DrStockPick.com

|Includes: CombiMatrix Corporation (CBMX)

drstock-2-3

signup3m

 

 

Crown Equity Holdings Inc. (OTCBB:CRWE) recently announced that it has launched its crwenewswire.fr website to provide news in France's native language. Crown Equity Holdings Inc. had previously launched its German website crwenewswire.de and is launching its Canadian website crwenewswire.ca shortly.

Crown Equity Holdings Inc. is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.

*****************

CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, reported the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects.

*****************

NovaBay Pharmaceuticals, Inc. (Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, snnounced that it will be presenting at the First Annual LifeTech Capital Miami Medical Investors' Conference, and the Fourth Annual Maxim Group Growth Conference.

*****************

Athersys, Inc. (Nasdaq:ATHX) has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010.

These grants were awarded related to ATHX's development of MultiStem for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation. MultiStem is currently being developed for the treatment of AMI, Graft vs. Host Disease (GvHD) following bone marrow transplant, inflammatory bowel disease, and stroke.

The Therapeutic Discovery Project grants totaled more than $730,000 in aggregate.

 

 

 THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.